These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30324219)

  • 1. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
    Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Yu X; Narayanan S; Vazquez A; Carpizo DR
    Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.
    Miller JJ; Gaiddon C; Storr T
    Chem Soc Rev; 2020 Oct; 49(19):6995-7014. PubMed ID: 32869798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological activation of p53 in cancer cells.
    Athar M; Elmets CA; Kopelovich L
    Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild type p53 reactivation: from lab bench to clinic.
    Selivanova G
    FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
    Farnebo M; Bykov VJ; Wiman KG
    Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
    Garg S; Singh J; Verma SR
    J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 activation by blocking Snail: a novel pharmacological strategy for cancer.
    Lee SH; Park BJ
    Curr Pharm Des; 2011; 17(6):610-7. PubMed ID: 21391911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
    Wawrzynow B; Zylicz A; Zylicz M
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological reactivation of p53 as a strategy to treat cancer.
    Zawacka-Pankau J; Selivanova G
    J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.